ArticleBMC infectious diseases2026
Subclinical atherosclerosis assessed by cardio-ankle vascular index and carotid intima-media thickness in people living with HIV receiving integrase inhibitor-based tenofovir regimens.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTenofovir alafenamide (TAF) is widely used in antiretroviral therapy due to its improved renal and bone safety compared to tenofovir disoproxil fumarate (TDF). However, concerns remain regarding its potential metabolic effects and cardiovascular risk. We aimed to compare lipid parameters and surrogate markers of subclinical atherosclerosis and arterial stiffness, namely carotid intima-media thickness (CIMT) and the cardio-ankle vascular index (CAVI), among people living with HIV (PLWH) receiving TAF- or TDF-based regimens and ART-naive individuals.
methodsIn this cross-sectional study, a total of 178 PLWH were included and classified into three groups: TAF-based therapy (n = 79), TDF-based therapy (n = 49), and ART-naive individuals (n = 53). Lipid profiles, CIMT, and CAVI were assessed contemporaneously during antiretroviral treatment and compared across groups. Multivariate logistic regression analysis was performed to identify factors independently associated with increased arterial stiffness.
resultsTotal cholesterol, triglyceride levels, CIMT, and CAVI were significantly higher in the TAF group compared with both the TDF and ART-naive groups (all p < 0.05). No significant differences were observed between the TDF and ART-naive groups. Subclinical atherosclerosis (CIMT ≥ 1 mm) and increased arterial stiffness (CAVI ≥ 8) were most frequently observed among individuals receiving TAF. In multivariate analysis, TAF use (p = 0.01) and age (p < 0.001) were independently associated with CAVI ≥ 8.
conclusionsAlthough TAF provides important renal and bone safety advantages, TAF-based regimens were associated with less favorable metabolic parameters and higher subclinical vascular markers in this cross-sectional cohort. These findings should be interpreted cautiously and do not establish a causal relationship. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.